CD38 and autoimmune thrombocytopenic purpura: Anti-CD38 daratumumab therapy allowed us to demonstrate the crucial contribution of ASCs in ITP, and to point toward a compartment other than the spleen that may serve in some patients as a source to reconstitute autoreactive ASC pools in circulation and in the bone marrow.